• Cleerly’s PARAMOUNT trial met its primary endpoint; results were presented November 7, 2026, at AHA Scientific Sessions in Chicago.
• AI-guided coronary plaque assessment improved diagnostic certainty compared with usual care based on stress testing in patients with suspected coronary artery disease.
• Plaque-guided care increased lipid-lowering therapy use, with greater reductions in LDL cholesterol than usual care.
• Fewer invasive angiograms ended without intervention; overall catheterization and revascularization rates did not increase.
• The findings are preliminary, with full results expected to be published in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cleerly Inc. published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.